 | Up a level |
Journal Article
Weller, Johannes 
ORCID: 0000-0001-5818-5392, Schaefer, Niklas, Schaub, Christina, Potthoff, Anna-Laura, Steinbach, Joachim P., Schlegel, Uwe, Sabel, Michael ORCID: 0009-0000-1485-7820, Hau, Peter, Seidel, Clemens, Krex, Dietmar, Goldbrunner, Roland, Pietsch, Torsten, Tzaridis, Theophilos, Zeyen, Thomas, Borger, Valeri, Guresir, Erdem, Vatter, Hartmut, Herrlinger, Ulrich and Schneider, Matthias
(2022).
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
J. Neuro-Oncol., 159 (1).
S. 95 - 102.
NEW YORK:
SPRINGER.
ISSN 1573-7373
Kebir, Sied, Schaub, Christina, Junold, Nina, Hattingen, Elke ORCID: 0000-0002-8392-9004, Schaefer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Hau, Peter, Goldbrunner, Roland, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Weller, Johannes ORCID: 0000-0001-5818-5392, Mack, Frederic, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Baehr, Oliver, Seidel, Clemens, Schlegel, Uwe, Schmidt-Graf, Friederike, Rohde, Veit, Borchers, Christian, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Haenel, Mathias, Sabel, Michael, Gerlach, Ruediger, Krex, Dietmar, Belka, Claus, Vatter, Hartmut, Proescholdt, Martin, Glas, Martin and Herrlinger, Ulrich
(2019).
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
J. Neuro-Oncol., 144 (3).
S. 501 - 510.
NEW YORK:
SPRINGER.
ISSN 1573-7373
Weller, Johannes ORCID: 0000-0001-5818-5392, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Hau, Peter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Baehr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Brehmer, Stefanie, Bullinger, Lars, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Schaub, Christina, Kebir, Sied, Stummer, Walter, Simon, Matthias, Fimmers, Rolf, Coch, Christoph, Glas, Martin, Herrlinger, Ulrich and Schaefer, Niklas
(2019).
Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.
Lancet Oncol., 20 (10).
S. 1444 - 1454.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-5488
Herrlinger, Ulrich, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Mack, Frederic, Steinbach, Joachim Peter, Schlegel, Uwe, Sabel, Michael, Hau, Peter ORCID: 0000-0003-3894-5053, Kortmann, Rolf-Dieter, Krex, Dietmar, Grauer, Oliver, Goldbrunner, Roland, Schnell, Oliver, Baehr, Oliver, Uhl, Martin, Seidel, Clemens, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Kowalski, Thomas, Ringel, Florian, Schmidt-Graf, Friederike, Suchorska, Bogdana, Brehmer, Stefanie, Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Renovanz, Miriam, Bullinger, Lars, Galldiks, Norbert ORCID: 0000-0002-2485-1796, Vajkoczy, Peter, Misch, Martin, Vatter, Hartmut, Stuplich, Moritz, Schaefer, Niklas, Kebir, Sied, Weller, Johannes ORCID: 0000-0001-5818-5392, Schaub, Christina, Stummer, Walter, Tonn, Joerg-Christian, Simon, Matthias, Keil, Vera C., Nelles, Michael, Urbach, Horst, Coenen, Martin, Wick, Wolfgang ORCID: 0000-0002-6171-634X, Weller, Michael, Fimmers, Rolf, Schmid, Matthias ORCID: 0000-0002-0788-0317, Hattingen, Elke ORCID: 0000-0002-8392-9004, Pietsch, Torsten, Coch, Christoph and Glas, Martin
(2019).
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Lancet, 393 (10172).
S. 678 - 689.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1474-547X